Differential Effects of Viremia and Microbial Translocation on Immune Activation in HIV-Infected Patients Throughout Ritonavir-Boosted Darunavir Monotherapy

Omar J. BenMarzouk-Hidalgo, PhD, Almudena Torres-Cornejo, PhD, Alicia Gutiérrez-Valencia, PhD, Rosa Ruiz-Valderas, MD, PhD, Pompeyo Viciana, MD, PhD, and Luis F. López-Cortés, MD, PhD

Abstract: The purpose of this article is to evaluate the evolution of microbial translocation (MT) and its role in CD4⁺ and CD8⁺ T cells immune activation (IA) in HIV-1-infected patients on ritonavir-boosted darunavir monotherapy (mtDRV/rtv).

Prospective study of consecutive HIV-1-infected patients switched to mtDRV/rtv as a simplification regimen. Subjects were classified according to the virological behavior during a 24-month follow-up as continuous undetectable viral load, blips, intermittent viremia, and virological failure (VF). MT was evaluated by plasma LPS and 16S genomic rDNA (16S rDNA) levels, whereas IA was assessed by the coexpression of HLA-DR and CD38 in CD4⁺ and CD8⁺ T cells, and plasma sCD14 levels.

Seventy-one patients were included in this sub-study of the MonDar cohort (ClinicalTrials.gov: NCT01505722). At baseline, CD4⁺ (ρ = 0.352, P = 0.01) and CD8⁺ T-cell activation (ρ = 0.468, P < 0.001) were correlated with time with viral suppression, but not with MT markers. A significant decrease in plasma LPS levels was found only in patients without VF (baseline, 77.8 vs month 24, 60.4 pg/mL; P < 0.001). Both plasma 16S rDNA and sCD14 levels were unchanged irrespective of the viral behavior. The only variable independently associated with a decrease in CD4⁺ and CD8⁺ T cells activation was an undetectable HIV-1 viremia (β = 0.478, P < 0.001 and β = 2.93, P = 0.005, respectively).

MT does not have a pivotal role in T-cell activation, at least in patients with long-term viral suppression. The viremic episodes and VF are the main factors related to CD4⁺ and CD8⁺ T-cells IA, even during mtDRV/rtv.

(Medicine 94(17):e781)

METHODS

INTRODUCTION

Several studies have highlighted the importance of microbial translocation (MT) as a pivotal mechanism for persistent immune activation (IA) during HIV-1 infection.1–4 This anamalous MT arises as a direct consequence of severe CD4⁺ T-cell depletion in the gastrointestinal tract and damage to the integrity of the intestinal mucosa.5–7 MT can be measured in plasma by direct quantification of bacterial products, including lipopolysaccharide (LPS), a component of the cell wall of gram-negative bacteria, as well as conserved sequences of 16S genomic rDNA (16S rDNA) common to most bacteria or other microbe-specific compounds. Both of them were positively correlated with CD8⁺ T-cell activation in untreated HIV infection and several longitudinal studies have shown important decreases in plasma LPS, 16S rDNA, and sCD14 levels after the initiation of ART, though without reaching the values of healthy individuals.1,5,8–14

In the past few years, ART simplification strategies, such as ritonavir-boosted protease inhibitor-based monotherapy (mtPI/rtv), have been explored in patients with long-standing virological suppression. Data from several clinical trials of lopinavir/ritonavir and ritonavir-boosted darunavir monotherapy (mtDRV/rtv) have shown that mtPI/rtv has a similar or slightly less efficacy than triple therapy to maintain viral load suppression.15–19 Even so, there is significant controversy regarding the use of this therapeutic strategy,20–25 and information about the impact of this therapeutic option on issues other than virological efficacy and safety is still scarce. Herein, we have assessed the evolution of MT and its role in CD4⁺ and CD8⁺ T cells IA profile in HIV-1-infected patients on mtDRV/rtv over a 24-month period.

MATERIAL AND METHODS

As previously described in detail,26–27 the MonDar cohort (Clinical-Trials.gov identifier: NCT01606722) prospectively enrolled 150 HIV-1-infected patients with virological suppression for ≥6 months who were switched to mtDRV/rtv (800/100 mg once daily) as a simplification strategy from January 2010 to April 2011. The study was conducted after obtaining informed consent according to the principles of the Declaration of Helsinki. The study was approved by the Ethics Committee in

Editor: Abrar Khan.

Received: January 22, 2015; revised: March 20, 2015; accepted: March 25, 2015.

From the Unidad Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva. Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Avenida Manuel Siurot, Sevilla, Spain.

Correspondence: Luis F. López-Cortés, Unidad Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospital Universitario Virgen del Rocío, Avenida Manuel Siurot, s/n. 41013, Sevilla, Spain (e-mail: llopezc@us.es).

This study was supported by a grant from Dirección Gerencia del Servicio Andaluz de Salud, Consejería de Salud, Junta de Andalucía (exp. SAS 111237).

LFL-C and PV have received unrestricted research funding, consultancy fees, and lecture fees from and have served on the advisory boards of Abbott, Bristol-Myers Squibb, Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme, Roche España, and ViV Healthcare. The other authors have no conflicts of interest to disclose.

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.

This is an open access article distributed under the Creative Commons Attribution-NonCommercial License, where it is permissible to download, share and reproduce the work in any medium, provided it is properly cited. The work cannot be used commercially.

ISSN: 0025-7974

DOI: 10.1097/MD.0000000000000781
Biomedical Research of Andalucía and the Spanish Agency for Medicines.

Patients, Follow-Up, and Samples

Clinical assessments and sampling were performed just before switching to mtDRV/rtv and quarterly thereafter, including biochemical and hematological profiles, CD4+ T cells counts, and plasma HIV-1 viremia (COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0; Roche, Branchburg, NJ). In this substudy, only patients with available samples just before and at month 6, 12, 18, and 24 after switching to mtDRV/rtv were included. Patients who presented virological failure (VF) on mtDRV/rtv were also followed up for 24 months after achieving virological control by triple therapy reintroduction or by encouraging adherence.

Patients were classified according to their virological behavior into 4 groups: continuous undetectable viremia (CUV) (<20 copies/mL); blips or transitory episodes of HIV-RNA >20 copies/mL, preceded and followed by undetectable viremia without changes in ART; VF, defined as 2 consecutive HIV-RNA >200 copies/mL; and intermittent viremia (IV) defined as episodes of detectable HIV-RNA during the follow-up yet without meeting the blip or VF criteria.

Laboratory Procedures

All samples were tested in duplicate. Plasma LPS and sCD14 were measured by the QCL-1000 Limulus Amebocyte Lysate kit (Lonza, Basel, Switzerland) and the Human sCD14 Quantikine ELISA kit (R&D Systems, Abingdon, Oxfordshire, UK), respectively, following manufacturer’s instructions. Plasma 16S rDNA was measured by quantitative polymerase chain reaction by using degenerate forward and reverse primers (8F: 5′-AGAGTTTGATYMTGGCTCAG-3′; 361R: 5′-CGGCATGAGGCAAGGCTG-3′) and a TaqMan probe (338P: 5′-FAM-TACGGGAGGCAGCAGT-BHQ1-3′). The IA profile was measured as the coexpression of HLA-DR and CD38 in both CD4+ and CD8+ T cells as previously described.

Statistical Analysis

Results are expressed as median and interquartile range for continuous variables and as number of cases and percentages for categorical variables. The Kruskal–Wallis and analysis of variance tests were performed to compare continuous variables, whereas the χ² and Fisher exact tests were run to compare categorical variables. The relationships between continuous variables were assessed by Spearman rank correlation coefficients (ρ test). The variables that were statistically significant in the univariate analysis were included in a multiple linear regression model. The differences were considered statistically significant for P values <0.05. The statistical analyses were performed using SPSS software (v. 19.0, Chicago, IL).

RESULTS

A total of 71 patients were included in this study and classified as CUV: 19 (26.8%); blips: 15 (21.1%); IV: 21 (29.6%); and VF: 16 (22.5%). Patients’ baseline characteristics are shown in Table 1. At baseline, a weak correlation was found between time with viral suppression and plasma levels of LPS (ρ = 0.311, P = 0.03), but not with 16S rDNA (ρ = 0.051, P = 0.67) or sCD14 (ρ = 0.075, P = 0.53). Moreover, time with viral suppression was inversely correlated with the percentages of HLA-DR+CD38+ CD4+ (ρ = 0.352, P = 0.01) and HLA-DR+CD38+ CD8+ T cells (ρ = 0.468, P = 0.001). The IA of CD4+ and CD8+ T cells were correlated with the sCD14 levels (ρ = 0.277, P = 0.05 and ρ = 0.412, P = 0.003), but not with LPS or 16S rDNA levels. Other epidemiological factors, such as age or hepatitis C virus coinfection, did not correlate with any of the MT or IA markers.

MT Evolution Over 24 Months on mtDRV/rtv

A significant decrease in plasma LPS levels was found in patients without VF (CUV, blips, and IV groups) (month 0, 77.8 [51.6–108.96] vs month 24, 60.4 pg/mL [51.8–74.4], P = 0.006; Figure 1A). By contrast, in those patients who experienced VF, the LPS levels remained unchanged in comparison with baseline values both at VF time and at month 24.

---

**TABLE 1. Patients’ Baseline Characteristics**

|         | CUV (n = 19) | Blips (n = 15) | IV (n = 21) | VF (n = 16) | P   |
|---------|-------------|---------------|-------------|-------------|-----|
| Age, y; M (IQR) | 47 (42–50) | 47 (38–51) | 44 (39–51) | 46 (42–49) | 0.87|
| Sex (male), n (%) | 14 (73.7) | 11 (73.3) | 19 (90.5) | 10 (62.5) | 0.25|
| Chronic hepatitis C, n (%) | 4 (21.1) | 4 (26.7) | 4 (19.0) | 4 (25.0) | 0.90|
| Time on HAART, mo; M (IQR) | 117 (86–160) | 59 (42–136) | 100 (66–130) | 83 (47–122) | 0.30|
| Time with viral suppression, mo; M (IQR) | 68 (40–97) | 39 (30–97) | 51 (34–84) | 42 (16–68) | 0.48|
| CD4+ T cell counts, cell/µL; M (IQR) | 545 (388–713) | 592 (502–908) | 560 (327–897) | 598 (435–784) | 0.50|
| Nadir CD4+ T cell counts, cell/µL; M (IQR) | 163 (32–224) | 144 (68–225) | 177 (94–264) | 125 (37–222) | 0.37|
| Zenith VL, log_{10} copies/mL; M (IQR) | 5.00 (4.63–5.78) | 6.05 (5.10–6.21) | 5.17 (4.97–5.36) | 5.2 (5.0–5.5) | 0.05|
| Blips in the previous 12 mo, n (%) | 2 (10.5) | 5 (33.3) | 8 (38.1) | 5 (31.3) | 0.15|
| HLA-DR+CD38+ CD4+ T cells, %; M (IQR) | 4.6 (3.9–6.8) | 5.1 (3.5–7.0) | 4.8 (2.7–6.7) | 6.1 (4.5–7.2) | 0.38|
| HLA-DR+CD38+ CD8+ T cells, %; M (IQR) | 5.0 (4.3–8.6) | 6.2 (4.5–8.5) | 5.8 (3.9–7.5) | 7.4 (6.3–10.6) | 0.09|
| sCD14, pg/mL; M (IQR) | 10.9 (8.6–13.2) | 11.2 (10.1–12.3) | 10.9 (8.8–13.2) | 10.1 (9.4–13.9) | 0.89|
| LPS, pg/mL; M (IQR) | 79.3 (62.1–145.8) | 63.8 (42.9–172.3) | 78.66 (54.0–102.0) | 76.1 (53.3–109.8) | 0.92|
| 16S rDNA, log_{10} copies/mL; M (IQR) | 5.4 (4.0–6.0) | 5.4 (5.6–5.8) | 5.3 (4.6–5.7) | 5.3 (5.0–5.4) | 0.68|

CUV = continuously undetectable viremia, HAART = highly active antiretroviral therapy, IQR = interquartile range, IV = intermittent viremia, LPS = lipopolysaccharide, M = median, VF = virological failure, VL = viral load.

---
Relationship Between IA, MT, and HIV-1 Viremia

The IA profiles of CD4+ and CD8+ T cells were related with the virological behavior after switching to mtrDR/rtv. During the 24 months, IA decreased in CUV patients (baseline HLA-DR CD38+ CD4+ T cells, 4.6% vs month 24, 4.0%, P = 0.01; baseline HLA-DR CD38+ CD8+ T cells, 5.3% vs month 24: 4.4%, P = 0.001), and remained stable in blips and in IV patients (baseline HLA-DR CD38+ CD4+ T cells, 5.0% vs month 24, 4.0%, P = 0.13; baseline HLA-DR CD38+ CD8+ T cells, 5.9% vs month 24, 4.8%, P = 0.75). By contrast, IA increased in patients with VF (baseline HLA-DR CD38+ CD4+ T cells, 6.1% vs month 24, 7.1%, P = 0.02; baseline HLA-DR CD38+ CD8+ T cells, 7.4% vs month 24, 9.4%, P = 0.06).

Throughout the follow-up, the changes in HLA-DR CD38+ CD4+ and CD8+ T cells were not associated to LPS or sCD14 levels, but weak correlations were found only between plasma 16S rDNA levels and HLA-DR CD38+ CD4+ (r = 0.286, P = 0.07) and CD8+ T cells (r = 0.331, P = 0.04).

On the other hand, there were no correlations between HIV-RNA and LPS levels (r = -0.085, P = 0.13) or 16S rDNA levels (r = 0.013, P = 0.82) or sCD14 levels (r = 0.013, P = 0.31) during the 24 months on mtrDR/rtv. In contrast, positive correlations were found between HIV-RNA and the percentages of HLA-DR CD38+ CD4+ (r = 0.102, P = 0.05) and CD8+ T cells (r = 0.162, P = 0.01). Finally, a multiple linear regression model showed that HIV-RNA was the only variable associated with changes in HLA-DR CD38+ CD4+ and CD8+ throughout the follow-up (β = 4.78, P < 0.001 and β = 2.93, P = 0.005, respectively).

DISCUSSION

We have assessed MT by 2 different markers (LPS and 16S rDNA) and a surrogate marker (sCD14). As in the study by Abad-Fernández et al.,14 no correlations of bacterial 16S rDNA with either with LPS or sCD14 were found. In addition, we also failed to find a relationship between LPS and sCD14 levels perhaps because sCD14 is an activation marker for monocytes, but not a direct or specific marker of MT.29 and stimuli other than MT could have a major influence on innate immunity activation in patients with a long time of viral suppression and immune reconstitution.30,31

Our results show that although plasma 16S rDNA and sCD14 levels remained stable throughout the 24 months on mtrDR/rtv irrespective of patients’ viral outcomes, LPS levels decreased, but only in patients without VF. This decline was more pronounced among patients with CUV, which might suggest a continuous recovery of the mucosal immune dysfunction and/or LPS clearance mechanisms, including the clearance by Kupffer cells.32,33 On the contrary, neither at baseline nor during the follow-up was CD4+ and CD8+ T cells IA related to MT markers. The only variable independently associated with a decrease in CD4+ and CD8+ T cells activation was an undetectable viremia throughout the follow-up. In a completely different clinical setting, Srivinusa et al.34 also found that HIV was the primary driving force behind the activation and proliferation of most subsets of both CD4 and CD8 T lymphocytes in HIV-infected patients, whereas MT had not an important role in this proliferation.

Nevertheless, this observational study have several limitations among which are the small sample size in each group of patients and that it was a single-arm trial, without a comparator group on triple therapy. Thus, these results need to be confirmed with larger prospective clinical studies including both types of treatment. Likewise, these results could be different in earlier treatment phases or in patients with higher immunological...
impairment. However, to date, there are few data on factors influencing the CD4+ and CD8+ T cells IA in HIV-1-infected patients on ritonavir-boosted protease inhibitor monotherapy. In this context, our results might help to clarify one of the several concerns about this maintenance strategy in patients with long-term viral suppression.

In summary, our results suggest that MT does not have a pivotal role in T-cell activation in patients with long-term viral suppression and relatively high CD4+ T-cell counts. The viremia and VF are the main factors related to CD4+ and CD8+ T cells IA, even during mtDRV/rtv.

ACKNOWLEDGMENTS

The authors are indebted to patients for their involvement in this study, and to M. Rodriguez, F. Cano, and R. Martin for their help with specimen processing.

REFERENCES

1. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. *Nat Med.* 2006;12:1365–1371.
2. Marchetti G, Bellistrì GM, Borghi E, et al. Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. *AIDS.* 2008;22:2035–2038.
3. Karlsson AC, Younger SR, Martin JN, et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. *AIDS.* 2004;18:981–989.
4. Richman DD, Margolis DM, Delaney M, et al. The challenge of finding a cure for HIV infection. *Science.* 2009;323:1304–1307.
5. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. *J Exp Med.* 2004;200:749–759.
6. Mattapallil JJ, Douek DC, Hill B, et al. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. *Nature.* 2005;434:1093–1097.
7. Mehadrus S, Poles MA, Tenner-Racz K, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. *J Exp Med.* 2004;200:761–770.
8. Wallet MA, Rodriguez CA, Yin L, et al. Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy. *AIDS.* 2010;24:1281–1290.
9. Rajasurian R, Booth D, Solomon A, et al. Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor alpha and microbial translocation. *J Infect Dis.* 2010;202:1254–1264.
10. Jiang W, Lederman M, Hunt P, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. *J Infect Dis.* 2009;199:1177–1185.
11. Reus S, Portilla J, Sánchez-Payá J, et al. Low-level HIV viremia is associated with microbial translocation and inflammation. *J Acquir Immune Defic Syndr.* 2013;62:129–134.
12. Pilakka-Kanhtikeel S, Kris A, Selvaraj A, et al. Immune activation is associated with increased gut microbial translocation in treatment-naive, HIV-infected children in a resource-limited setting. *J Acquir Immune Defic Syndr.* 2014;66:16–24.
13. d’Ettoire G, Baroncelli S, Micci L, et al. Reconstitution of intestinal CD4 and Th17 T cells in antiretroviral therapy suppressed HIV-infected subjects: implication for residual immune activation from the results of a clinical trial. *PLoS One.* 2014;9:e109791.
30. Marchetti G, Cozzi-Lepri A, Merlini E, et al. Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. *AIDS*. 2011;25:1385–1394.

31. Marchetti G, Nasta P, Bai F, et al. Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients. *PLoS One*. 2012;7:e32028.

32. Guadalupe M, Reay E, Sankaran S, et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. *J Virol*. 2003;77:11708–11717.

33. Balagopal A, Ray SC, De Oca RM, et al. Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitution. *AIDS*. 2009;23:2397–2404.

34. Srinivasula S, Lempicki RA, Adelsberger JW, et al. Differential effects of HIV viral load and CD4 count on proliferation of naive and memory CD4 and CD8 T lymphocytes. *Blood*. 2011;118:262–270.